EICHORPublic-registry site landscape for NCT04987294, “Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease”, a Hyperuricemia study sponsored by Allena Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04987294 (registry record) |
| Study title | Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease |
| Sponsor | Allena Pharmaceuticals |
| Condition(s) | Hyperuricemia; Gout; Chronic Kidney Diseases |
| Phase | PHASE2 |
| Listed sites | 17 |
| Intervention(s) | ALLN-346, Placebo |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04987294.
Eichor generates a preliminary site-risk snapshot for NCT04987294 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Hyperuricemia trials
← Eichor home · All tracked trials · Hyperuricemia studies · Weekly briefs
